Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities (2005)
Chapter: Appendix A: Information Gathering Workshop Agenda
Appendix A
Information Gathering Workshop Agenda
Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings
Tuesday, January 27, 2004
Room 100, Keck Building
500 5th Street, NW
Washington, DC 2001
8:00-8:20 | Welcome, Introduction of Committee, and Statement of Charge |
Dr. James Curran and Dr. Haile Debas | |
Committee Cochairs |
The Opportunity
8:20-8:45 | The Challenge of HIV/AIDS in 2004 and the WHO 3 × 5 Program |
Dr. Jim Kim | |
Advisor to the Director-General | |
World Health Organization | |
Geneva, Switzerland |
8:45-9:10 | The Global Funds’ Lessons Learned Regarding ARV Drug Scale-up in Resource-Constrained Settings |
Dr. Bernhard Schwartlander | |
Director | |
Strategic Information and Measurement | |
Global Fund to Fight AIDS, TB, and Malaria | |
Geneva, Switzerland | |
9:10-9:35 | The U.S. Emergency Plan for Antiretroviral Scale-up: The Latest Programmatic Developments |
Dr. Joe O’Neil | |
Deputy Coordinator | |
Office of the Global AIDS Coordinator | |
Department of State | |
Washington, DC | |
9:35-9:55 | General Discussion |
9:55-10:15 | BREAK |
Antecedents
10:15-10:40 | Durability of ARV Therapy: U.S. Experience and Its Implications for Resource-Constrained Settings |
Dr. Robert Redfield | |
Cofounder and Director of Clinical Care and Research Division, Institute of Human Virology | |
University of Maryland | |
Baltimore, MD | |
10:40-11:05 | A U.S. Clinical Perspective on the Implications of ARV Resistance for Resource-Constrained Settings |
Dr. Steven Deeks | |
Associate Clinical Professor of Clinical Medicine | |
University of California, San Francisco | |
San Francisco, CA | |
11:05-11:30 | Lessons Learned from the Scale-up of ARV Treatment in Brazil |
Dr. Mauro Schechter | |
Professor of Infectious Diseases | |
Universidade Federal do Rio de Janeiro, Brazil |
11:30-11:55 | Lessons Learned from the Use of ARVs in Very Low-Resource Settings: The Haiti Experience |
Dr. Daniel Fitzgerald | |
Groupe Haitien d’Étude du Sarcome de Kaposi et des infections Opportunistes (GHESKIO) Port-au-Prince, Haiti, and | |
Division of International Medicine and Infectious Diseases | |
Cornell University Medical College | |
New York, NY | |
11:55-12:20 | MSF Perspectives on ARV Administration: Experiences from 20 countries and 10,000 Patients |
Ms. Rachel Cohen | |
U.S. Director, Campaign for Access to Essential Medicines | |
Médecins sans Frontières | |
New York, NY | |
12:20-12:50 | General Discussion |
12:50-1:50 | LUNCH |
Clinical Principles for ARV Scale-up Programs
1:50-2:15 | The 2003 WHO Guidelines for ARV Use: Perspectives from a User |
Dr. John Idoko | |
Professor | |
Jos University Teaching Hospital | |
Jos, Nigeria | |
2:15-2:40 | MTCT-Plus Initiative: Perspectives from a Multicountry Comprehensive HIV Care and Treatment Program |
Dr. Wafaa El-Sadr | |
Professor | |
Mailman School of Public Health | |
Columbia University and Harlem Hospital | |
New York, NY |
2:40-3:05 | The Role of the Laboratory in Managing ARV Care in a Country with Highly Limited Resources |
| Dr. Brooks Jackson |
| Baxley Professor and Director of Pathology |
| Johns Hopkins University School of Medicine |
| Baltimore, MD |
3:05-3:30 | The Social and Behavioral Dimensions of Adherence: Implications for Patient Education |
| Dr. Carla Makhlouf Obermeyer |
| Scientist |
| Department of HIV/AIDS |
| World Health Organization |
| Geneva, Switzerland |
3:30-3:50 | General Discussion |
3:50-4:10 | BREAK |
4:10-4:35 | Preventing Mother-to-Child Transmission: Issues of Therapy and Resistance |
| Dr. Lynne Mofenson |
| Pediatric, Adolescent and Maternal AIDS Branch |
| Center for Research for Mothers and Children |
| National Institute of Child Health and Human Development |
| National Institutes of Health |
| Bethesda, MD |
4:35-5:00 | Pediatric Considerations for ARV Programs in Resource-Constrained Settings |
| Dr. Mark Kline |
| Chief, Retrovirology Clinic |
| Professor of Pediatrics |
| Director, Baylor International Pediatric AIDS Initiative |
| Baylor College of Medicine/Texas Children’s Hospital |
| Houston, TX |
5:00-5:25 | The Integration of Counseling, Prevention, and ARV Programs |
| Dr. Sam Dooley |
| Division of HIV/AIDS Prevention |
| Centers for Disease Control and Prevention |
| Atlanta, GA |
5:25-6:00 | Wrap-up Comments and Discussion |
Wednesday, January 28, 2004
Management Principles for Scale-up of ARV Programs
8:00-8:05 | Opening Comments |
| Dr. James Curran and Dr. Haile Debas |
| Committee Cochairs |
8:05-8:30 | Principles of Design and Scale-up for National Clinical Care Programs and Applications to the WHO 3 × 5 Targets |
| Dr. M. Rashad Massoud |
| Vice President and Director |
| Quality and Performance Institute |
| University Research Co., LLC |
| Bethesda, MD |
8:30-8:55 | An Overview of Health Care Manpower, Health Care Infrastructure, and Economics in Select Resource-Poor Countries |
| Mr. Mead Over |
| Lead Economist |
| Development Research Group |
| World Bank |
| Washington, DC |
8:55-9:20 | The Role of Community Mobilization in the Scale-up of ARV programs |
| Ms. Emi MacLean |
| Médecins sans Frontières |
| New York, NY |
9:20-9:45 | Distribution of ARVs: Issues of Security, Logistics, and Quality |
| Ms. Yasmin Chandani |
| HIV/AIDS Advisor for DELIVER |
| John Snow, Inc. |
| Arlington, VA |
9:45-10:10 | Large Scale Training for ARV Providers: Observations from the United States |
| Dr. John McNeil |
| Chief, Infectious Diseases |
| Howard University |
| PI, National Minority AIDS Education and Training Center |
| Washington, DC |
10:10-10:30 | General Discussion |
10:30-10:50 | BREAK |
10:50-11:15 | Perspectives on Purchasing First and Second Line ARVs |
| Ms. Lynn Margherio |
| Executive Vice President |
| The Clinton Foundation HIV/AIDS Initiative |
11:15-11:40 | Delivering ARVs: The Economic Consequences of Resistance |
| Dr. Stefano Bertozzi |
| Director |
| Economics and Policy |
| Center of Research on Health Systems |
| National Institute of Public Health |
| Cuernavaca, Mexico |
11:40-12:00 | General Discussion |
12:00-1:00 | LUNCH |
The Path Forward
1:00-1:25 | Assessing Readiness for ARV Program Implementation |
| Dr. Eric Goosby |
| Chief Executive Officer |
| Pangea Global AIDS Foundation |
| San Francisco, CA |
1:25-1:50 | Specific Questions for Operations Research in the Scale-up of ARV Treatment Programs in Low-Resource Settings |
| Dr. Tom Quinn |
| Professor of Medicine |
| Johns Hopkins University School of Medicine |
| Baltimore, MD |
1:50-2:15 | The Role of Statistical Prediction Methods for Managing ARV Scale-up Programs |
| Dr. Victor De Gruttola |
| Professor of Biostatistics |
| Harvard School of Public Health |
| Boston, MA |
2:15-2:40 | Ethical Issues in the Scale-up of ARV Programs in Resource-Poor Settings |
| Ms. Angela Wasunna |
| Lawyer/Bioethicist |
| Associate for International Programs |
| The Hastings Center |
| Garrison, NY |
2:40-3:05 | Discussion |
3:05-3:30 | BREAK |
3:30-3:55 | Information Management Considerations in Managing ARV Programs |
| Mr. Ronaldo Lima |
| International AIDS Vaccine Initiative |
| New York, New York |
3:55-4:20 | ARV Resistance: Epidemiologic Implications and Public Health Surveillance |
| Dr. Diane Bennett |
| World Health Organization |
| Geneva, Switzerland |
4:20-4:45 | Monitoring and Evaluation for ARV Programs in Resource-Poor Settings |
| Dr. Paul DeLay |
| UNAIDS |
| Geneva, Switzerland |
4:45-5:10 | The South African Plan for ARV Scale-up |
| Dr. Tony Mbewu, |
| Executive Director |
| Medical Research Council of South Africa |
| Capetown, South Africa |
5:10-6:00 | Discussion and Wrap-up |
